Editorials

219 Serum Potassium in Dual Renin-Angiotensin-Aldosterone System Blockade
Stephen L. Seliger and Linda F. Fried
See related article on page 295.

222 Early Dialysis Initiation, a Look from the Rearview Mirror to What’s Ahead
Steven J. Rosansky
See related article on page 310.

225 Progressive Inflammation and Wasting in Patients with ESRD
George A. Kaysen
See related article on page 318.

227 Rehospitalization after Living Kidney Donation
Bryan N. Becker and Yolanda T. Becker
See related article on page 355.

Original Articles

Acid/Base and Electrolyte Disorders

229 Use of Desmopressin Acetate in Severe Hyponatremia in the Intensive Care Unit
Cédric Rafat, Frédérique Schortgen, Stéphane Gaudry, Fabrice Bertrand, Romain Miguel-Montanes, Vincent Labbé, Jean-Damien Ricard, David Hajage, and Didier Dreyfuss

Acute Kidney Injury /Acute Renal Failure

239 Fibroblast Growth Factor-23 and the Long-Term Risk of Hospital-Associated AKI among Community-Dwelling Older Individuals
Jeremiah R. Brown, Ronit Katz, Joachim H. Ix, Ian H. de Boer, David S. Siscovick, Morgan E. Grams, Michael Shlipak, and Mark J. Sarnak

Chronic Kidney Disease

247 Medication Treatment Complexity and Adherence in Children with CKD
Tom D. Blydt-Hansen, Christopher B. Pierce, Yi Cai, Dmitri Samsonov, Susan Massengill, Marva Moxey-Mims, Bradley A. Warady, and Susan L. Furth

Clinical Immunology and Pathology

255 Renal Interstitial Infiltration and Tertiary Lymphoid Organ Neogenesis in IgA Nephropathy
Guangchang Pei, Rui Zeng, Min Han, Panli Liao, Xuan Zhou, Yueqiang Li, Ying Zhang, Ping Liu, Chunxiu Zhang, Xiaocheng Liu, Ying Yao, and Gang Xu

Clinical Nephrology

265 The Histopathologic Spectrum of Kidney Biopsies in Patients with Inflammatory Bowel Disease
Josephine M. Ambruza, Patrick D. Walker, and Christopher P. Larsen
271 Cyclosporine C2 Monitoring for the Treatment of Frequently Relapsing Nephrotic Syndrome in Children: A Multicenter Randomized Phase II Trial
Kazumoto Iijima, Mayumi Sako, Mari Saito Oba, Shuichi Ito, Hiroshi Hataya, Ryojiro Tanaka, Yoko Ohwada, Koichi Kamei, Kenji Ishikura, Nahoko Yata, Kandai Nozu, Masataka Honda, Hidefumi Nakamura, Michio Nagata, Yasuo Ohashi, Koichi Nakanishi, and Norishige Yoshikawa, for the Japanese Study Group of Kidney Disease in Children

279 Renal Flare as a Predictor of Incident and Progressive CKD in Patients with Lupus Nephritis
Samir V. Parikh, Haikady N. Nagaraja, Lee Hebert, and Brad H. Rovin

Critical Care Nephrology

285 Predictive Performance of Urine Neutrophil Gelatinase-Associated Lipocalin for Dialysis Requirement and Death Following Cardiac Surgery in Neonates and Infants
Mirela Bojan, Stéphanie Vicca, Vanessa Lopez-Lopez, Agnes Mogenet, Philippe Pouard, Bruno Falissard, and Didier Journois

Diabetes and The Kidney

295 Potassium Handling with Dual Renin-Angiotensin System Inhibition in Diabetic Nephropathy
Peter N. Van Buren, Beverley Adams-Huet, Mark Nguyen, Christopher Molina, and Robert D. Toto
See related editorial on page 219.

Epidemiology and Outcomes

302 Incidence and Renal Survival of ESRD in the Young Taiwanese Population
Tzu-Chun Tsai, Yu-Chun Chen, Chiao-Wei Lo, Wei-Shu Wang, Su-Shun Lo, Gau-Jun Tang, and Peck-Foong Thien

310 Provider and Care Characteristics Associated with Timing of Dialysis Initiation
Yelena Slinin, Haifeng Guo, Suying Li, Jiannong Liu, Benjamin Morgan, Kristine Ensrud, David T. Gilbertson, Allan J. Collins, and Areef Ishani
See related editorial on page 222.

ESRD and Chronic Dialysis

318 Clinical Predictors of Decline in Nutritional Parameters over Time in ESRD
See related editorial on page 225.

326 Longitudinal Study of Small Solute Transport and Peritoneal Protein Clearance in Peritoneal Dialysis Patients
Zanzhe Yu, Mark Lambie, and Simon J. Davies

Genetics

335 HLA-DQA1 and PLA2R1 Polymorphisms and Risk of Idiopathic Membranous Nephropathy
Gemma Bullich, José Ballarín, Artur Oliver, Nadia Ayasreh, Irene Silva, Sheila Santín, Montserrat M. Díaz-Encarnación, Roser Torra, and Elisabet Ars

Mineral Metabolism/Bone Disease

344 Disordered FGF23 and Mineral Metabolism in Children with CKD
Anthony A. Portale, Myles Wolf, Harald Jüppner, Shari Messinger, Juhi Kumar, Katherine Wesseling-Perry, George J. Schwartz, Susan L. Furth, Bradley A. Warady, and Isidro B. Salusky

Renal Transplantation

355 Hospitalizations Following Living Donor Nephrectomy in the United States
Jesse D. Schold, David A. Goldfarb, Laura D. Buccini, James R. Rodrigue, Didier Mandelbrot, Emily L. G. Heaphy, Richard A. Fatica, and Emilio D. Poggio
See related editorial on page 227.
What’s the diagnosis? The patient presented with multiple small and large renal calculi which occupied the majority of the renal collecting system (cover image). Based on stone size and the potential for renal damage, treatment was recommended. The density of the stones on computed tomography (CT) scan was \(< 400\) Hounsfield units, consistent with uric acid composition. A 4 mm stone which the patient previously passed per urethra was analyzed by infrared spectroscopy and confirmed the diagnosis of 100% uric acid composition. First-line therapy for an asymptomatic uric acid stone that requires treatment is alkalanization of the urine to dissolve the stone as the solubility of uric acid in urine increases with increasing urine pH – if this fails, endourologic management is often considered if the stone burden is large. Common medications used for dissolution of uric acid calculi include sodium bicarbonate and potassium citrate. For this particular patient, potassium citrate 30 mEq three times per day was prescribed (total of 90 mEq daily). A follow-up CT scan 6 months later demonstrated complete dissolution of the stone burden but there was a question as to whether the patient has a left ureteropelvic junction obstruction versus extra-renal pelvis (image below). Diuretic renography was performed to evaluate for obstruction and the results showed no evidence of ureteropelvic junction obstruction, thus this was an extra-renal pelvis, which can be found in \(~5\%\) of the population. The patient is now on a maintenance prophylactic dose of potassium citrate 10 mEq po three times per day and has been stone free for 1 year on this regimen. (Images and text provided by Brian Eisner, Massachusetts General Hospital, Harvard Medical School)